The Wisconsin DNR approved permits for Enbridge to reroute Line 5. Here are the next steps in the controversial project.

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...

Investors were spooked by slowing sales growth for EYLEA and lack of revenue ... because the median P/E for the company over the past 5 years is at 18, and now the company is valued at 25-27 ...

Ola Electric has confirmed the launch of an electric three-wheeler in the first or second quarter of the upcoming financial ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

According to the report, the Abu Dhabi market is well-positioned for growth, driven by new developers entering the market and ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Third Quarter 2024 Earnings Conference Call. My name is Sherry, ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

Updated figures provided through the department’s Urban Development Program (UDP) show completions are down 18 per cent on the five-year average. Loading Developer lobby group Urban Taskforce ...

Q3 2024 ReportResults in line for Q3 2024 with sales momentum increasing throughout the period and into Q4GIG Software Plc ...

That denial was partially due to the pipeline route’s conflicts with local county siting laws. “Our focus continues to be on working with landowners and ensuring the long-term viability of ...